PSR Biopharma

PSR Biopharma is a biotechnology company focused on developing next-generation oral therapies for metabolic diseases, including obesity and type 2 diabetes. The company leverages a proprietary oral delivery platform designed to overcome the bioavailability challenges typically associated with peptide-based drugs. By converting injectable treatments into convenient oral formats, PSR Biopharma aims to improve patient adherence and expand access to highly effective metabolic regulators. Their lead programs focus on incretin-based mechanisms, such as GLP-1 receptor agonists, targeting large and growing markets in metabolic health.